AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11850308 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 28
Study 10621536 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autografting
Number of subjects: 0
Study 10621536 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival rotation autograft and inferior conjunctival transposition flap
Number of subjects: 0
Study 10621536 — intervention group
Group type: EXPERIMENTAL
Intervention: Human amniotic membrane adjunct use
Number of subjects: 0
Study 8803365 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss treatment (21.1 +/- 8.4 kg lost after 6 months)
Number of subjects: 55
Study 1897510 — intervention group
Group type: EXPERIMENTAL
Intervention: Postage stamped return envelope
Number of subjects: 10047
Study 1897510 — intervention group
Group type: COMPARATOR
Intervention: Franked return envelope
Number of subjects: 10047
Study 1897510 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenotification letter
Number of subjects: 10047
Study 1897510 — intervention group
Group type: COMPARATOR
Intervention: No prenotification letter
Number of subjects: 10047
Study 6123837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir therapy (500 mg/m2 intravenously 3 times daily for 5 days)
Number of subjects: 31
Study 6123837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6123837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 31
Study 30977398 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weekly group sessions of manualized memory rehabilitation plus usual care
Number of subjects: 328
Study 30977398 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 328
Study 28535810 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate 400 mg qid for 21 days
Number of subjects: 84
Study 28535810 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study 28535810 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 84
Study 25495359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 84
Study 25495359 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy (ET)
Number of subjects: 84
Study 25495359 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL) control
Number of subjects: 84
Study 23811491 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 206
Study 23811491 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 206
Study 23811491 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy
Number of subjects: 206
Study 23811491 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 206
Study 21519566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium disilicate FPDs
Number of subjects: 37
Study 21519566 — intervention group
Group type: COMPARATOR
Intervention: Porcelain‐fused‐to‐metal FPDs
Number of subjects: 37
Study 17901953 — intervention group
Group type: EXPERIMENTAL
Intervention: PF (cisplatin 100 mg/m² i.v. Day 1 and 5-FU 1,000 mg/m² per day i.v. continuous infusion D1-D5, every 21 days)
Number of subjects: 206
Study 17901953 — intervention group
Group type: EXPERIMENTAL
Intervention: UFTVP (cisplatin 100 mg/m² i.v. Day 1; UFT 200 mg/m² per day p.o. D1-D21 and vinorelbine 25 mg/m² i.v. D1 and D8, every 21 days)
Number of subjects: 206
Study 17901953 — intervention group
Group type: EXPERIMENTAL
Intervention: UFTVP
Number of subjects: 206
Study 16098945 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision
Number of subjects: 60
Study 16098945 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch
Number of subjects: 60
Study 16098945 — intervention group
Group type: EXPERIMENTAL
Intervention: Smell
Number of subjects: 60
Study 16098945 — intervention group
Group type: EXPERIMENTAL
Intervention: Audition
Number of subjects: 60
Study 16098945 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste
Number of subjects: 60
Study 16098945 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual products
Number of subjects: 60
Study 16098945 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation types
Number of subjects: 60
Study 11875728 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised beta-carotene supplementation
Number of subjects: 513
Study 11875728 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 513
Study 10463173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated with two acellular and one whole-cell pertussis vaccine
Number of subjects: 129
Study 10463173 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 129
Study 10463173 — intervention group
Group type: EXPERIMENTAL
Intervention: B. pertussis strains used in vaccines
Number of subjects: 129
Study 10463173 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains isolated from vaccinated groups
Number of subjects: 129
Study 7841012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanguard
Number of subjects: 20
Study 7841012 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries Meter L
Number of subjects: 20
Study 7841012 — intervention group
Group type: COMPARATOR
Intervention: Visual examination
Number of subjects: 20
Study 7841012 — intervention group
Group type: COMPARATOR
Intervention: Radiographic examination
Number of subjects: 20
Study 2192564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 19
Study 2192564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 840125 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon)
Number of subjects: 151
Study 840125 — intervention group
Group type: COMPARATOR
Intervention: Control (no Silymarin)
Number of subjects: 151
Study 6818169 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazone
Number of subjects: 120
Study 6818169 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazone plus dextropropoxyphene
Number of subjects: 120
Study 6818169 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 120
Study 31232252 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 50
Study 31232252 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Workshop (BHW)
Number of subjects: 50
Study 29440016 — intervention group
Group type: COMPARATOR
Intervention: Point-of-care C-reactive protein test (POC CRP)
Number of subjects: 2227
Study 29440016 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention to elicit parental concern combined with safety net advice (BISNA)
Number of subjects: 2227
Study 29440016 — intervention group
Group type: COMPARATOR
Intervention: Combination of POC CRP and BISNA
Number of subjects: 2227
Study 29440016 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 2227
Study 27799585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclopentolate HCL 1% applied to closed eyelids
Number of subjects: 87
Study 27799585 — intervention group
Group type: COMPARATOR
Intervention: Cyclopentolate HCL 1% applied directly to open eyelids
Number of subjects: 87
Study 24447343 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis group (NLR and hs-CRP)
Number of subjects: 51
Study 24447343 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis group (AVP)
Number of subjects: 51
Study 24447343 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis group (CIMT)
Number of subjects: 51
Study 24447343 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 51
Study 22180415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 40
Study 22180415 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 20217230 — intervention group
Group type: EXPERIMENTAL
Intervention: Forensic assertive community treatment (FACT)
Number of subjects: 0
Study 20217230 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 17058272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography of the tibial nerve in patients with vasculitic neuropathy
Number of subjects: 8
Study 17058272 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography of the tibial nerve in control subjects
Number of subjects: 8
Study 15720933 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultations
Number of subjects: 278
Study 15720933 — intervention group
Group type: COMPARATOR
Intervention: Surgery consultations
Number of subjects: 278
Study 12086199 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide HFA (340 microg daily)
Number of subjects: 235
Study 12086199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (6400 microg daily)
Number of subjects: 235
Study 12086199 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) (336 microg daily)
Number of subjects: 235
Study 12086199 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide HFA, BDP, and Cromolyn sodium
Number of subjects: 235
Study 10429772 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (10 micrograms x kg‐1)
Number of subjects: 148
Study 10429772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron (12.5 mg)
Number of subjects: 148
Study 10429772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of droperidol and dolasetron (10 micrograms x kg‐1 + 12.5 mg)
Number of subjects: 148
Study 10429772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 10429772 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 148
Study 7593515 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlaparoscope < 2.0 mm diameter under general anaesthesia (group I)
Number of subjects: 41
Study 7593515 — intervention group
Group type: COMPARATOR
Intervention: Microlaparoscope < 2.0 mm diameter under analgesic sedation plus local anaesthesia (group II)
Number of subjects: 41
Study 2105990 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 22
Study 2105990 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 22
Study 2105990 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (15 minutes before exercise)
Number of subjects: 22
Study 2105990 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide aerosol (4 weeks treatment)
Number of subjects: 22
Study 2105990 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 22
Study 91498 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG patterns during cognitive tasks
Number of subjects: 23
Study 30891718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention deprexis®
Number of subjects: 0
Study 30891718 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27918712 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care (SC) program
Number of subjects: 156
Study 27918712 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 156
Study 25719620 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blocks (PVB) and total intravenous anesthesia
Number of subjects: 66
Study 25719620 — intervention group
Group type: COMPARATOR
Intervention: Sham subcutaneous injections and standardized general anesthesia
Number of subjects: 66
Study 25719620 — intervention group
Group type: EXPERIMENTAL
Intervention: DN4 screening tool
Number of subjects: 66
Study 25719620 — intervention group
Group type: EXPERIMENTAL
Intervention: IASP grading system
Number of subjects: 66
Study 24977310 — intervention group
Group type: COMPARATOR
Intervention: 6-session family-based HIV prevention intervention targeting general parenting, gender roles, and parent-youth communication about sex.
Number of subjects: 99
Study 21615424 — intervention group
Group type: EXPERIMENTAL
Intervention: Good side effects with positive character description
Number of subjects: 0
Study 21615424 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects consistent with character and motives
Number of subjects: 0
Study 21615424 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 19514478 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts
Number of subjects: 55
Study 19514478 — intervention group
Group type: COMPARATOR
Intervention: Cages (titanium interbody implants)
Number of subjects: 55
Study 17576071 — intervention group
Group type: EXPERIMENTAL
Intervention: C1‐INH (1000 UI)
Number of subjects: 80
Study 17576071 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 80
Study 15139169 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective equipment
Number of subjects: 301
Study 11952432 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 microg/kg/min remifentanil
Number of subjects: 30
Study 11952432 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 microg/kg/min remifentanil
Number of subjects: 30
Study 9615498 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine
Number of subjects: 425
Study 8591720 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 14C-labeled meloxicam (intravenous infusion)
Number of subjects: 4
Study 8591720 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 14C-labeled meloxicam (oral solution)
Number of subjects: 4
Study 2649022 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (20 ml containing 9% gamma-linolenic acid)
Number of subjects: 18
Study 2649022 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 18
Study 897632 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF)
Number of subjects: 0
Study 897632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 0
Study 29544520 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported contraception use
Number of subjects: 50
Study 29544520 — intervention group
Group type: EXPERIMENTAL
Intervention: Calendar data on effective contraception use
Number of subjects: 50
Study 28302958 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 855
Study 25590186 — intervention group
Group type: EXPERIMENTAL
Intervention: Early double-guidewire (EDG) technique
Number of subjects: 274
Study 25590186 — intervention group
Group type: COMPARATOR
Intervention: Repeated single-guidewire (RSG) technique
Number of subjects: 274
Study 23296464 — intervention group
Group type: EXPERIMENTAL
Intervention: TruScreen
Number of subjects: 181
Study 23296464 — intervention group
Group type: COMPARATOR
Intervention: Pap smear
Number of subjects: 181
Study 23296464 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TruScreen to Pap smear
Number of subjects: 181
Study 21193343 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 40
Study 21193343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18504873 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercises
Number of subjects: 79
Study 18504873 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 79
Study 16630342 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 0
Study 16630342 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (acupuncture at non-specific points)
Number of subjects: 0
Study 16630342 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 0
Study 16630342 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 14577658 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA supplementation (2.1 g daily for 45 days)
Number of subjects: 16
Study 14577658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11320440 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory confrontation naming using digitized environmental sounds
Number of subjects: 0
Study 11320440 — intervention group
Group type: EXPERIMENTAL
Intervention: Free classification task
Number of subjects: 0
Study 11320440 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained classification task
Number of subjects: 0
Study 8923023 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplements of vitamins (with or without other antioxidants)
Number of subjects: 0
Study 8923023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre and/or a low-fat diet
Number of subjects: 0
Study 8923023 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modifications
Number of subjects: 0
Study 8923023 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements
Number of subjects: 0
Study 1738797 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of theophylline (400 mg)
Number of subjects: 20
Study 1738797 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of theophylline (300 mg b.d. for 4 weeks)
Number of subjects: 20
Study 1738797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6395773 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 0.75 mg/kg/day
Number of subjects: 50
Study 6395773 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 1.25 mg/kg/day
Number of subjects: 50
Study 30736773 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional periarticular injection (40 mg methylprednisolone, 150 mg ropivacaine, 0.1 mg epinephrine)
Number of subjects: 43
Study 30736773 — intervention group
Group type: COMPARATOR
Intervention: No additional injection
Number of subjects: 43
Study 29248359 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa enzyme replacement therapy (ERT), administered weekly for 96 weeks.
Number of subjects: 173
Study 29248359 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa ERT (continuously treated patients), administered weekly for 96 weeks.
Number of subjects: 173
Study 29248359 — intervention group
Group type: COMPARATOR
Intervention: Control group from Morquio A Clinical Assessment Program (MorCAP), untreated cohort, N=94.
Number of subjects: 173
Study 29248359 — intervention group
Group type: COMPARATOR
Intervention: Comparison between MOR-005 and MorCAP for mobility and self-care domains at 2 years.
Number of subjects: 173
Study 27156854 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 24
Study 27156854 — intervention group
Group type: COMPARATOR
Intervention: Baseline (placebo)
Number of subjects: 24
Study 26488319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fifth intercostal space (ICS), anterior axillary line (AAL)
Number of subjects: 25
Study 26488319 — intervention group
Group type: COMPARATOR
Intervention: Second intercostal space (ICS), midclavicular line (MCL)
Number of subjects: 25
Study 26488319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sites (Fifth ICS AAL and Second ICS MCL)
Number of subjects: 25
Study 23207729 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol and ozagrel for 14 days (n = 50)
Number of subjects: 100
Study 23207729 — intervention group
Group type: COMPARATOR
Intervention: ozagrel alone for 14 days (n = 50)
Number of subjects: 100
Study 21492498 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 40
Study 21492498 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 1 mg
Number of subjects: 40
Study 18444492 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) - 10 units injected into both nasal cavities
Number of subjects: 38
Study 18444492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) - 3x2 injections into both nasal cavities for 4 weeks
Number of subjects: 38
Study 18444492 — intervention group
Group type: COMPARATOR
Intervention: Placebo - intranasal physiologic saline
Number of subjects: 38
Study 17294999 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 44
Study 17294999 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg lidocaine
Number of subjects: 44
Study 17294999 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg remifentanil
Number of subjects: 44
Study 17294999 — intervention group
Group type: COMPARATOR
Intervention: 3 ml of 0.9% sodium chloride (control group)
Number of subjects: 44
Study 12712868 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 60
Study 12712868 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 60
Study 10721318 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 mm copper filtration
Number of subjects: 20
Study 10721318 — intervention group
Group type: COMPARATOR
Intervention: Control group (no copper filtration)
Number of subjects: 20
Study 8874914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block (DPNB) only (Group A, n = 122)
Number of subjects: 250
Study 8874914 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA) + DPNB (Group B, n = 128)
Number of subjects: 250
Study 8874914 — intervention group
Group type: EXPERIMENTAL
Intervention: DPNB only (Group A)
Number of subjects: 250
Study 8874914 — intervention group
Group type: COMPARATOR
Intervention: GA + DPNB (Group B)
Number of subjects: 250
Study 7930473 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (INTRON A, Schering‐Plough Corporation) 5 million unit subcutaneously, three times a week for 24 weeks
Number of subjects: 56
Study 7930473 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha‐2b with prednisolone in decreasing doses of 60, 40, 20 mg for 6 weeks
Number of subjects: 56
Study 3332914 — intervention group
Group type: EXPERIMENTAL
Intervention: ciladopa 15 mg b.i.d.
Number of subjects: 32
Study 3332914 — intervention group
Group type: EXPERIMENTAL
Intervention: ciladopa 5 mg b.i.d.
Number of subjects: 32
Study 3332914 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 3332914 — intervention group
Group type: EXPERIMENTAL
Intervention: ciladopa
Number of subjects: 32
Study 29860362 — intervention group
Group type: EXPERIMENTAL
Intervention: Social modeling of side effects (placebo treatment)
Number of subjects: 96
Study 29860362 — intervention group
Group type: COMPARATOR
Intervention: Female participants seated with a female model
Number of subjects: 96
Study 26319220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sennoside
Number of subjects: 131